Potential of Mesalazine Therapeutic Drug Monitoring by Measuring Fecal Excretion in Patients With Ulcerative Colitis.

van de Meeberg, Maartje M; Verheij, Elwin R; Fidder, Herma H; Bouma, Gerd; Huitema, Alwin D R; Oldenburg, Bas

van de Meeberg, Maartje M; Verheij, Elwin R; Fidder, Herma H; Bouma, Gerd; Huitema, Alwin D R; Oldenburg, Bas.

Afiliación

van de Meeberg MM; Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht University, Utrecht.
Verheij ER; Department of Gastroenterology and Hepatology, Amsterdam UMC, Vrije Universiteit Amsterdam, AGEM Research Institute, Amsterdam.
Fidder HH; TNO Healthy Living, Zeist.
Bouma G; Department of Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht University, Utrecht.
Huitema ADR; Department of Gastroenterology and Hepatology, Amsterdam UMC, Vrije Universiteit Amsterdam, AGEM Research Institute, Amsterdam.
Oldenburg B; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht.

Ther Drug Monit ; 45(5): 668-675, 2023 10 01.

Article en En | MEDLINE | ID: mdl-36823707

Asunto(s)

Colitis Ulcerosa; Mesalamina; Adulto; Humanos; Mesalamina/uso terapéutico; Colitis Ulcerosa/tratamiento farmacológico; Colitis Ulcerosa/metabolismo; Antiinflamatorios no Esteroideos/uso terapéutico; Estudios Transversales; Monitoreo de Drogas

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Colitis Ulcerosa / Mesalamina Tipo de estudio: Observational_studies / Prevalence_studies / Risk_factors_studies Límite: Adult / Humans Idioma: En Revista: Ther Drug Monit Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google